Access Consortium Good Manufacturing Practice (GMP) Statement

15 November 2022 – MHRA published access consortium statement on GMP inspections reliance and recognition.

The Access Consortium was formed in 2007 by ‘like-minded’ regulatory authorities to promote greater regulatory collaboration and alignment of regulatory requirements. The Consortium was initially formed by the regulatory authorities from Australia (Therapeutic Goods Administration), Canada (Health Canada), Singapore (Health Sciences Authority), and Switzerland (Swissmedic). More recently, the United Kingdom’s Medicines and Healthcare products Regulatory Agency joined the Consortium. Its goal is to maximize international cooperation, reduce duplication, and increase each agency’s capacity to ensure consumers have timely access to high quality, safe and effective therapeutic products.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /